Login
Abbott plans to spin off nutrition unit that generates $8.5 billion in annual sales
The separation of the maker of Similac and Ensure is expected by the end of 2027 and will leave 2026 guidance unchanged
Reading view
Novartis raised its profit outlook even as a drug trial failure led to a $1.9 billion charge
Core operating income guidance moved from a low-single-digit decline to flat or low-single-digit growth; net income fell 70%
GSK is expecting its cancer drug clinical pipeline to nearly double in 2027
Oncology chief Hesham Abdullah said GSK has about 15 cancer assets in trials and could run 19 to 20 late-stage studies next year
Judge denied Novo Nordisk bid to block Eli Lilly weight-loss drug ads
Judge Zahid Quraishi said Novo Nordisk failed to show irreparable harm; the drugmaker says its false advertising suit continues
